Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Mohamad Mohty(Sorbonne Université)
Cited by 534
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
One million haemopoietic stem-cell transplants: a retrospective observational study
|The Lancet Haematology|2015|434